The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...

A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...

GOV.UK states that the Medicines and Healthcare products Regulatory Agency (MHRA) "approved a product licence for the ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) made a number of recommendations at its November ...

European regulators initially said in July that the drug's benefits did not outweigh its risks.View on euronews ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

AI-driven MRI solution, icobrain aria receives US FDA clearance for safer Alzheimer’s treatment: Boston Saturday, November 16, 2024, 16:00 Hrs [IST] icometrix, a g ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...

Pamela, 73, has lived with Alzheimer’s for two years. David is an Alzheimer’s advocate. More medications are emerging to ...